BNT3212 / BioNTech - LARVOL DELTA

In the last quarter, BioNTech initiated several signal-seeking clinical trials to evaluate pumitamig with the Company’s proprietary assets (GlobeNewswire) - "(i) In August, the first patient was dosed in a Phase 1/2 clinical trial (NCT07079631) to evaluate...BNT314/GEN1059 in combination with pumitamig and chemotherapy in patients with advanced CRC; (ii) Also in August, the first patient was dosed in a Phase 1/2 clinical trial (NCT07070232) to evaluate pumitamig in combination with...BNT326/YL202 and BNT326/YL202 as monotherapy in advanced solid tumors; (iii) In September, the first patient was dosed in a Phase 1/2 clinical trial (NCT07147348) to evaluate BNT3212...as monotherapy and in combination with pumitamig in patients with advanced solid tumors; (iv) In October, the first patient was dosed in a Phase 1/2 clinical trial (NCT07111520) to evaluate...BNT326/YL202 in combination with pumitamig in advanced NSCLC."

Trial status • Colorectal Cancer • Non Small Cell Lung Cancer

In September, the first patient was dosed in a Phase 1/2 clinical trial (NCT07147348) to evaluate BNT3212, a novel bispecific ADC candidate targeting EGFR and HER3, as monotherapy and in combination with pumitamig in patients with advanced solid tumors. (The Manila Times)

Trial status • Solid Tumor

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=375 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Solid Tumor